Novofem (Estradiol | Norethisterone Acetate, Estradiol)

The estradiol component binds to estrogen receptors, restoring hormonal activity that alleviates vasomotor and urogenital symptoms. Norethisterone acetate activates progesterone receptors, counteracting estrogen‑driven endometrial proliferation and reducing the risk of hyperplasia.

The appropriate dose of Novofem is determined by the prescribing clinician based on the individual’s age, severity of symptoms, and overall health profile. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Novofem is generally not recommended for use during pregnancy or while breastfeeding because hormonal therapy can affect fetal development and milk composition. Women who are pregnant, planning pregnancy, or nursing should discuss alternative options with their healthcare provider.

To request Novofem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Novofem combines both estrogen and progestogen in a single tablet, which can simplify therapy compared with separate estrogen‑only products that require an added progestogen for endometrial protection. This combination may improve adherence but shares similar efficacy and safety profiles to other combined HRT regimens.

Novofem tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Novofem is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, stroke, and severe allergic reactions. Patients with a history of clotting disorders, cardiovascular disease, or estrogen‑dependent cancers should be closely monitored or may need alternative therapy.

Novofem is contraindicated in women with known or suspected estrogen‑dependent tumors, active or past thromboembolic disease, severe liver dysfunction, or unexplained vaginal bleeding. It should also be avoided in individuals who are pregnant or breastfeeding unless a clinician determines the benefits outweigh the risks.